No price history available.
Key financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 317 | 319 | 367 | 445 | 470 | 501 | 423 | N/A | N/A |
| Operating profit | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | £m | 34 | 42 | 39 | 59 | 51 | 26 | 48 | N/A | N/A |
| EPS reported | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Established in 1959 and headquartered in Abingdon, UK, Oxford Instruments plc operates as a global technology enterprise dedicated to the innovation, development, manufacturing, rental, sale, and maintenance of sophisticated scientific instruments and systems. Its global footprint extends across the United Kingdom, China, Japan, the United States, Germany, the broader European continent, and the rest of Asia, serving international markets. The company's operations are divided into three core business units: Materials & Characterisation, Research & Discovery, and Service & Healthcare. The extensive product lineup includes advanced atomic force microscopy devices, along with vital tools for research and development that serve a wide array of sectors, including semiconductors, renewable energy, mining, metallurgy, and forensic science. It also supplies specialized etch and deposition processing equipment and solutions critical for applications in power and radio frequency devices, VCSELs/lasers, two-dimensional materials, augmented reality, biomems, failure analysis, HBLEDs, infrared sensors, MEMS/sensors, and quantum technologies. Furthermore, Oxford Instruments offers a comprehensive range of low-temperature systems, encompassing wet and magnet systems, advanced instrumentation, and bespoke custom solutions. The company's portfolio also features optical imaging products; Nuclear Magnetic Resonance (NMR) instruments, including spectrometers, quality control/assurance analyzers, and rock core analyzers, which are indispensable across diverse fields such as agriculture, food, automotive, aviation, construction, chemicals, environmental science, illicit drug testing, mining, pharmaceuticals, polymers, rock core analysis, textiles, and educational institutions. The enterprise also provides support products for MRI and CT imaging technologies, alongside scientific cameras, spectroscopy solutions, microscopy systems, and proprietary software. These are integral to applications in astronomy, bio-imaging and life sciences, energy generation and storage, forensics and environmental monitoring, photonics, quantum technology, semiconductors, microelectronics, and data storage. Moreover, Oxford Instruments manufactures X-ray tubes, power supplies, and integrated X-ray sources, catering to the analytical, medical imaging, food quality and packaging inspection, and industrial non-destructive testing (NDT) markets.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Established in 1959 and headquartered in Abingdon, UK, Oxford Instruments plc operates as a global technology enterprise dedicated to the innovation, development, manufacturing, rental, sale, and maintenance of sophisticated scientific instruments and systems. Its global footprint extends across the United Kingdom, China, Japan, the United States, Germany, the broader European continent, and the rest of Asia, serving international markets. The company's operations are divided into three core business units: Materials & Characterisation, Research & Discovery, and Service & Healthcare. The extensive product lineup includes advanced atomic force microscopy devices, along with vital tools for research and development that serve a wide array of sectors, including semiconductors, renewable energy, mining, metallurgy, and forensic science. It also supplies specialized etch and deposition processing equipment and solutions critical for applications in power and radio frequency devices, VCSELs/lasers, two-dimensional materials, augmented reality, biomems, failure analysis, HBLEDs, infrared sensors, MEMS/sensors, and quantum technologies. Furthermore, Oxford Instruments offers a comprehensive range of low-temperature systems, encompassing wet and magnet systems, advanced instrumentation, and bespoke custom solutions. The company's portfolio also features optical imaging products; Nuclear Magnetic Resonance (NMR) instruments, including spectrometers, quality control/assurance analyzers, and rock core analyzers, which are indispensable across diverse fields such as agriculture, food, automotive, aviation, construction, chemicals, environmental science, illicit drug testing, mining, pharmaceuticals, polymers, rock core analysis, textiles, and educational institutions. The enterprise also provides support products for MRI and CT imaging technologies, alongside scientific cameras, spectroscopy solutions, microscopy systems, and proprietary software. These are integral to applications in astronomy, bio-imaging and life sciences, energy generation and storage, forensics and environmental monitoring, photonics, quantum technology, semiconductors, microelectronics, and data storage. Moreover, Oxford Instruments manufactures X-ray tubes, power supplies, and integrated X-ray sources, catering to the analytical, medical imaging, food quality and packaging inspection, and industrial non-destructive testing (NDT) markets.
